Kura Oncology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Kura Oncology, Inc. on June 21, 2022. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol KURA.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (April 25, 2022), there were 66,636,105 shares outstanding, with 59,343,019 shares present at the meeting. Stockholders approved the following proposals:
- Proposal 1 (Election of Directors): Helen Collins, M.D., and Carol Schafer were elected with overwhelming support. Thomas Malley was elected but received significant opposition, with 11,814,417 votes withheld.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation paid to named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of the voting process.
Key Facts for Investor Verification
- Verify the specific reasons for the significant number of votes withheld for director Thomas Malley (approx. 20% of votes cast).
- Confirm the tenure of the newly elected Class II directors, which extends until the 2025 Annual Meeting.
- Review the full proxy statement for details on the executive compensation package that was approved.